Navigation Links
U.S. District Court Rules in Favor of Lilly in Amylin Litigation

INDIANAPOLIS, June 8, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of California ruled in Lilly's favor, vacating a temporary restraining order and denying a request by Amylin Pharmaceuticals for a preliminary injunction that sought to impose restrictions on the Lilly Diabetes sales force and other relief. Amylin recently filed litigation involving the two companies' diabetes collaboration agreement.

"We are pleased with the Court's decision to vacate the temporary restraining order and deny Amylin's request for a preliminary injunction," said Robert A. Armitage, senior vice president and general counsel for Lilly "We have complied with our contractual obligations under our agreements with Amylin, and done so in a manner fully consistent with all applicable laws. We believe that Amylin's allegations against Lilly are entirely without merit and we fully expect to prevail in this litigation."

Enrique Conterno, president of Lilly Diabetes, said, "We are committed to offering a broad range of treatment options, including important new therapies, to people with diabetes and their health care providers. There is more work to be done, and we will continue to work hand in hand with all of our diabetes partners to achieve better outcomes for patients."

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at  C-LLY

This press release contains forward-looking statements about our alliance with Amylin, and it reflects Lilly's current beliefs. There are substantial risks and uncertainties in the process of drug development and commercialization. Further, we cannot predict the outcome of any litigation with Amylin or its effect on our collaboration. For further discussion of risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.


SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
2. U.S. District Court Order Maintains Patent Exclusivity for Lillys Cymbalta
3. Watson Confirms District Court Ruling in Generic Fentora® Patent Suit
4. Watson Announces Favorable District Court Ruling in Generic Fentora® Patent Suit
5. Watson Announces Favorable District Court Ruling in Generic Mucinex® Patent Suit
6. Sensipar® Patents Upheld By District Court
7. Winner Medical Honored with Shenzhen Baoan District Quality Award
8. U.S. District Court Rules from Bench in Lillys Favor, Confirms Validity of Alimta Patent
9. German District Court Finds RENASYS™ GO NPWT System Non-infringing
10. Capital District Health Authority and IWK Health Centre to Implement Anesthesia Information Management System
11. Renhuang Wins Bid to Supply All-Natural Products to Guangzhou Military District
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015   VolitionRx Limited (NYSE MKT: ... tests for a broad range of cancer types and other ... Micro Conference, which will be held December 1 - 3 in ... VolitionRx will be David Kratochvil , Chief Financial Officer ... Investor Relations. ® blood-based tests for colorectal ...
(Date:11/30/2015)... Nov. 30, 2015  Precision Image Analysis Inc. ... pleased to announce a dramatic expansion of its ... Building on its ISO-9001:2008 certification for its Quality ... Core Lab protocols and procedures. This expansion enables ... activities.  Their Core Lab services include design and ...
(Date:11/30/2015)... BOSTON , November 30, 2015 ... medicines directed at up to 10 G protein-coupled receptor ... PFE ) to research and develop potential new medicines ... targets across multiple therapeutic areas. --> Heptares ... development company and wholly-owned subsidiary of Sosei Group Corporation ...
Breaking Medicine Technology:
(Date:11/29/2015)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... Women's Excellence is once again accredited by the American Institute ... peer review process that allows practices to demonstrate that they meet or ...
(Date:11/29/2015)... ... November 29, 2015 , ... NewsWatch featured X-wing as part of its monthly ... Forstrom, a technology expert and special reporter for NewsWatch, conducted the review and shared ... , It’s the future because flying cars are about to become a reality. Where’s ...
(Date:11/29/2015)... ... 29, 2015 , ... Doctors who missed a case of mesothelioma in a ... mesothelioma and push for a diagnosis, especially in people exposed to asbestos. Surviving Mesothelioma ... read it now. , Researchers at Gifu Prefectural Tajimi Hospital in Japan ...
(Date:11/29/2015)... ... November 29, 2015 , ... Key Housing, a top-rated corporate housing ... December, 2015, featured apartment community: Epic. In showcasing this featured apartment community in San ... Bay Area rental market to efficiently find housing suitable to their needs by showcasing ...
(Date:11/28/2015)... ... 2015 , ... Trying to relax on a couch can actually be uncomfortable, ... this design due to personal experience with a bad back," he said. , This ... as well as increases support. It also makes it easier to eat, do other ...
Breaking Medicine News(10 mins):